Bioinformatic analysis of large and complex omics datasets has become increasingly useful
in modern day biology by providing a great depth of information, with its application to …

Alzheimer's disease (AD) is determined by various pathophysiological mechanisms starting
10–25 years before the onset of clinical symptoms. As multiple functionally interconnected …

Alzheimer's disease (AD) is a neurodegenerative disorder that affects millions of people
worldwide. Growing evidence suggests that the gut microbiome (GM) plays a pivotal role in …

As it is well known, the gut is one of the primary sites in any host for xenobiotics, and the
many microbial metabolites responsible for the interactions between the gut microbiome and …

Alzheimer's disease (AD) is a central neurodegenerative disorder characterized by
behavioral disturbance and progressive cognitive impairment, and it is common in pre …

Medical laboratory services enable precise measurement of thousands of biomolecules and
have become an inseparable part of high-quality healthcare services, exerting a profound …

Mass spectrometry focusing on small endogenous molecules has become an integral part of
biomarker discovery in the pursuit of an in-depth understanding of the pathophysiology of …

Metabolomics samples like human urine or serum contain upwards of a few thousand
metabolites, but individual analytical techniques can only characterize a few hundred …

Alzheimer's disease (AD) is a complex and multifactorial neurodegenerative disease, which
is currently diagnosed via clinical symptoms and nonspecific biomarkers (such as Aβ1–42, t …

Recently, measurable peripheral biomarkers in the plasma of patients with Alzheimer's
disease (AD) have gained considerable clinical interest. Several studies have identified one …